Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Toronto - Delayed Quote CAD

Cardiol Therapeutics Inc. (CRDL.TO)

1.4900
-0.0100
(-0.67%)
At close: April 25 at 4:00:00 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for CRDL.TO

Recent News: CRDL.TO

View More
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Newsfile 10 days ago
We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
Simply Wall St. 24 days ago
Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Cardiol Therapeutics Announces Year-End 2024 Update on Operations
Newsfile 25 days ago
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Newsfile last month
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
Newsfile 2 months ago
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Newsfile 2 months ago
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis
GlobeNewswire 4 months ago
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Newsfile 5 months ago
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
GlobeNewswire 5 months ago
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis

Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
Newsfile 6 months ago
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option

Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
Newsfile 6 months ago
View More

Related Tickers

MDP.TO Medexus Pharmaceuticals Inc.
2.7000
-2.53%
 
GHG.CN Global Hemp Group Inc.
0.0200
0.00%
 
DHB.V Delivra Health Brands Inc.
0.1800
+12.50%
 
BHC.TO Bausch Health Companies Inc.
7.53
-0.66%
 
TLRY.TO Tilray Brands, Inc.
0.6900
+1.47%
 
CL.CN Cresco Labs Inc.
1.1800
+7.27%
 
PLTH.CN Planet 13 Holdings Inc.
0.4000
+11.11%
 
AYR-A.CN Ayr Wellness Inc.
0.3250
0.00%
 
RDY Dr. Reddy's Laboratories Limited
13.79
-1.50%
 
LABS.TO MediPharm Labs Corp.
0.0900
0.00%